Aims and Scope of Expert Opinion on Biological Therapy
Expert Opinion on Biological Therapy is a monthly peer-reviewed medical journal covering research on all aspects of biological therapy, including gene therapy and gene transfer technologies, therapeutic peptides and proteins, vaccines and antibodies, and cell- and tissue-based therapies. The journal is published by Taylor & Francis and the editor-in-chief is Michael Morse (Duke University Hospital). The journal was established in 2001 and according to the Journal Citation Reports, it has a 2017 impact factor of 3.974. The journal is also indexed in MEDLINE. Less
Key Metrics
CiteScore 

7.2
Eigenfactor 

0.005 - 0.01
H-Index 

96
Impact Factor 

< 5
SJR 

Q1Pharmacology

SNIP 

1.01
Recommended pre-submission checks
Powered by 

Topics Covered on Expert Opinion on Biological Therapy
Expert Opinion on Biological Therapy Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2001 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Expert Opinion on Biological Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Expert Opinion on Biological Therapy
Reframing guselkumab’s benefit in ulcerative colitis: insights from QUASAR and emerging evidence
- 27 Nov 2025
- Expert Opinion on Biological Therapy
Reply to: reframing guselkumab’s benefit in ulcerative colitis: insights from QUASAR and emerging evidence
- 25 Nov 2025
- Expert Opinion on Biological Therapy
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis
- 20 Nov 2025
- Expert Opinion on Biological Therapy
Ten-year trend of rituximab use for hematological malignancies: a multiregional real-world study using the Italian VALORE distributed database network
- 8 Nov 2025
- Expert Opinion on Biological Therapy
Real-world effectiveness and predictors of complete skin clearance (PASI 100) with anti-IL-23 monoclonal antibodies in moderate-to-severe psoriasis: a retrospective cohort study
- 6 Nov 2025
- Expert Opinion on Biological Therapy
Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach
- 5 Nov 2025
- Expert Opinion on Biological Therapy
Reframing guselkumab’s benefit in ulcerative colitis: insights from QUASAR and emerging evidence
- 27 Nov 2025
- Expert Opinion on Biological Therapy
Reply to: reframing guselkumab’s benefit in ulcerative colitis: insights from QUASAR and emerging evidence
- 25 Nov 2025
- Expert Opinion on Biological Therapy
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis
- 20 Nov 2025
- Expert Opinion on Biological Therapy
Ten-year trend of rituximab use for hematological malignancies: a multiregional real-world study using the Italian VALORE distributed database network
- 8 Nov 2025
- Expert Opinion on Biological Therapy
Real-world effectiveness and predictors of complete skin clearance (PASI 100) with anti-IL-23 monoclonal antibodies in moderate-to-severe psoriasis: a retrospective cohort study
- 6 Nov 2025
- Expert Opinion on Biological Therapy
Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach
- 5 Nov 2025
- Expert Opinion on Biological Therapy